Chen Jibing, Lv Youyong, Mu Feng, Xu Kecheng
Fuda Cancer Hospital of Jinan University, Guangzhou 510665, China,
Beijing Cancer Hospital of Peking University, Beijing 100142, China.
Onco Targets Ther. 2019 Apr 5;12:2531-2538. doi: 10.2147/OTT.S200414. eCollection 2019.
In this study, we present the case of a 56-year-old patient with renal clear cell carcinoma who developed lung metastases 13 months after nephrectomy and subsequently received tyrosine kinase inhibitor (sunitinib) and PD-1 antibody (nivolumab) immunotherapy, which failed to control the progression of the disease. The patient further developed metastases to the left pleura, bilateral hilar lymph nodes, liver, right lower kidney, scapula, left sixth rib, right tonsil, and other organs. There was severe anemia, requiring weekly blood transfusions. Karnofsky score was 30. After receiving mixed bacterial vaccine (MBV) consisting of 6 kinds of heat-inactivated bacteria plus Poly I:C, the patient's condition rapidly improved, systemic metastases gradually reduced in size or disappeared, anemia was corrected, and the patient was able to resume normal life and work. MBV treatment in the setting of failure of previous immunotherapy treatment appears to have achieved objective response for this patient with metastatic renal clear cell carcinoma, which has lasted more than 20 months.
在本研究中，我们报告了一例56岁肾透明细胞癌患者的病例。该患者在肾切除术后13个月出现肺转移，随后接受酪氨酸激酶抑制剂（舒尼替尼）和PD-1抗体（纳武单抗）免疫治疗，但未能控制疾病进展。患者进一步出现左胸膜、双侧肺门淋巴结、肝脏、右肾下极、肩胛骨、左第六肋骨、右扁桃体等器官转移。患者出现严重贫血，需要每周输血。卡诺夫斯基评分30分。在接受由6种热灭活细菌加聚肌胞组成的混合细菌疫苗（MBV）后，患者病情迅速改善，全身转移灶逐渐缩小或消失，贫血得到纠正，患者能够恢复正常生活和工作。在先前免疫治疗失败的情况下，MBV治疗似乎使该转移性肾透明细胞癌患者获得了客观缓解，且缓解持续超过20个月。
